Utah Medical Products (UTMD) AI Stock Analysis

• Market Cap: $191.90M
• Dividend Yield: 2.15%
• Average Volume (3M): 15.88K
• Price to Earnings (P/E): 16.9
• Beta (1Y): 0.47
• Revenue Growth: -12.35%
• EPS Growth: -17.20%
• Country: US
• Employees: 155
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 0.82
• Shares Outstanding: 3,203,672
• 10 Day Avg. Volume: 20,525
• 30 Day Avg. Volume: 15,884
• PEG Ratio: -1.16
• Price to Book (P/B): 1.83
• Price to Sales (P/S): 5.26
• P/FCF Ratio: 14.75
• Enterprise Value/Market Cap: 0.61
• Enterprise Value/Revenue: 3.04
• Enterprise Value/Gross Profit: 5.56
• Enterprise Value/Ebitda: 6.67
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 63 Neutral
• Price Target: $63.00 ▲(13.17% Upside)

Utah Medical Products' strong financial performance is the most significant factor, supported by solid profitability and a robust balance sheet. However, technical analysis indicates bearish momentum, which weighs down the overall score. The valuation is neutral, providing neither a strong positive nor negative impact.

Positive Factors

Balance Sheet Health

A strong balance sheet with low leverage enhances financial stability, allowing UTMD to invest in growth opportunities without significant financial risk.

Cash Flow Generation

Strong cash flow generation supports ongoing operations and strategic investments, providing UTMD with the flexibility to fund growth initiatives and manage economic fluctuations.

Profitability

High profitability margins indicate efficient operations and cost management, which can sustain competitive advantages and shareholder returns over time.

Negative Factors

Revenue Growth Decline

Declining revenue growth could signal challenges in market expansion or product demand, potentially impacting long-term business momentum and profitability.

Earnings Growth Decline

A decline in earnings growth can affect investor confidence and limit the company's ability to reinvest in business development, potentially hindering future growth.

Market Position Challenges

Operating in a competitive market with declining revenue growth may challenge UTMD's ability to maintain its market position, affecting long-term strategic goals.

Utah Medical Products Business Overview & Revenue Model

Company Description

Utah Medical Products, Inc. (UTMD) is a leading medical device company focused on developing and manufacturing high-quality medical products primarily for the healthcare sector. Founded in 1978 and headquartered in Midvale, Utah, the company specializes in the design of innovative, proprietary products that cater to the needs of hospitals and healthcare professionals. UTMD's product lines include disposable devices used in critical areas such as neonatal care, urology, and surgical procedures, emphasizing safety and efficacy.

How the Company Makes Money

Utah Medical Products generates revenue through the sale of its medical devices to hospitals, clinics, and healthcare providers. The company's revenue model is primarily based on direct sales of its proprietary products, which are sold both domestically and internationally. Key revenue streams include sales from its neonatal product line, urology devices, and surgical instruments. Additionally, UTMD engages in partnerships with distributors and healthcare institutions to expand its market reach and increase product adoption. The company's emphasis on innovation and regulatory compliance helps maintain a competitive edge, contributing to sustained earnings through consistent demand for its medical devices.

Utah Medical Products Financial Statement Overview

Summary

Utah Medical Products demonstrates strong financial health with solid profitability, a robust balance sheet, and strong cash flow generation. Despite concerns over revenue growth, the company's efficient operations and low leverage position it well for future stability and potential growth.

Income Statement

Utah Medical Products shows strong profitability with a consistent net profit margin above 30% and a solid EBIT margin. However, the company has experienced a decline in revenue growth, with a negative growth rate in the TTM period. Despite this, the gross profit margin remains healthy, indicating efficient cost management.

Balance Sheet

The balance sheet is robust with a very low debt-to-equity ratio, indicating minimal leverage and financial risk. The return on equity is stable, reflecting efficient use of equity to generate profits. The equity ratio is strong, suggesting a solid capital structure with a high proportion of equity financing.

Cash Flow

Cash flow metrics are strong, with a high operating cash flow to net income ratio, indicating good cash generation relative to earnings. Free cash flow growth has been positive in the TTM period, although it has fluctuated in previous years. The free cash flow to net income ratio is close to 1, showing effective cash conversion from profits.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	38.83M	40.90M	50.22M	52.28M	49.05M	42.18M
Gross Profit	21.19M	24.14M	30.04M	32.20M	30.92M	25.55M
EBITDA	17.67M	16.44M	24.75M	26.87M	26.16M	20.92M
Net Income	12.55M	13.87M	16.64M	16.47M	14.79M	10.80M
Balance Sheet
Total Assets	120.80M	122.54M	135.46M	123.87M	115.64M	111.75M
Cash, Cash Equivalents and Short-Term Investments	82.18M	82.98M	92.87M	75.05M	60.97M	51.59M
Total Debt	256.00K	338.00K	295.00K	341.00K	396.00K	335.00K
Total Liabilities	3.27M	5.11M	7.14M	9.62M	8.50M	8.92M
Stockholders Equity	117.53M	117.43M	128.31M	114.25M	107.14M	102.82M
Cash Flow
Free Cash Flow	14.02M	14.60M	21.64M	20.33M	20.65M	19.28M
Operating Cash Flow	14.13M	14.83M	22.28M	21.15M	21.20M	20.14M
Investing Cash Flow	-333.00K	-208.00K	-639.00K	-818.00K	-552.00K	-860.00K
Financing Cash Flow	-21.39M	-23.84M	-4.17M	-5.48M	-10.90M	-10.73M

Utah Medical Products Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 55.67
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For UTMD, the sentiment is Positive. The current price of 55.67 is below the 20-day moving average (MA) of 57.41, below the 50-day MA of 56.49, and below the 200-day MA of 56.70, indicating a bullish trend. The MACD of 0.64 indicates Negative momentum. The RSI at 66.67 is Neutral, neither overbought nor oversold. The STOCH value of 82.40 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for UTMD.

Utah Medical Products Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
INFU	68 Neutral	$176.31M	33.41	9.95%	―	6.23%	283.88%
UTMD	63 Neutral	$191.90M	16.95	9.59%	2.15%	-12.35%	-17.20%
KRMD	59 Neutral	$261.72M	-72.99	-21.71%	―	22.12%	69.19%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SMTI	42 Neutral	$217.58M	-5.52	-27.19%	―	30.55%	-340.19%